Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Biomolecules|March 6, 2021
Recent Advances in Cancer ImmunotherapyKenichi Suda
Cells|July 2, 2021
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> MutationsKenichi Suda, Tetsuya Mitsudomi
Molecular Cancer Research : MCR|August 1, 2013
Unintentional weakness of cancers: the MEK-ERK pathway as a double-edged swordKenichi Suda, Tetsuya Mitsudomi
Progress in Tumor Research|April 15, 2014
Successes and limitations of targeted cancer therapy in lung cancerKenichi Suda, Tetsuya Mitsudomi
Translational Lung Cancer Research|January 25, 2021
Emerging oncogenic fusions other than <i>ALK</i>, <i>ROS1</i>, <i>RET</i>, and <i>NTRK</i> in NSCLC and the role of fusions as resistance mechanisms to targeted therapyKenichi Suda, Tetsuya Mitsudomi
Kyobu Geka. the Japanese Journal of Thoracic Surgery|February 9, 2017
[Molecular Biology for Surgical Treatment of Lung Cancer]Kenichi Suda, Tetsuya Mitsudomi
Cells|December 24, 2025
Current Status and Future Challenges of Liquid BiopsyShuta Ohara, Kenichi Suda
Kyobu Geka. the Japanese Journal of Thoracic Surgery|March 6, 2022
[Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer]Kenichi Suda, Tetsuya Mitsudomi
Archives of Toxicology|May 19, 2015
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivityKenichi Suda, Tetsuya Mitsudomi
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Development of personalized treatments in lung cancer: focusing on the <i>EGFR</i> mutations and beyondKenichi Suda, Tetsuya Mitsudomi
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Biomolecules|March 6, 2021
Recent Advances in Cancer ImmunotherapyKenichi Suda
Cells|July 2, 2021
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> MutationsKenichi Suda, Tetsuya Mitsudomi
Molecular Cancer Research : MCR|August 1, 2013
Unintentional weakness of cancers: the MEK-ERK pathway as a double-edged swordKenichi Suda, Tetsuya Mitsudomi
Progress in Tumor Research|April 15, 2014
Successes and limitations of targeted cancer therapy in lung cancerKenichi Suda, Tetsuya Mitsudomi
Translational Lung Cancer Research|January 25, 2021
Emerging oncogenic fusions other than <i>ALK</i>, <i>ROS1</i>, <i>RET</i>, and <i>NTRK</i> in NSCLC and the role of fusions as resistance mechanisms to targeted therapyKenichi Suda, Tetsuya Mitsudomi
Kyobu Geka. the Japanese Journal of Thoracic Surgery|February 9, 2017
[Molecular Biology for Surgical Treatment of Lung Cancer]Kenichi Suda, Tetsuya Mitsudomi
Cells|December 24, 2025
Current Status and Future Challenges of Liquid BiopsyShuta Ohara, Kenichi Suda
Kyobu Geka. the Japanese Journal of Thoracic Surgery|March 6, 2022
[Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer]Kenichi Suda, Tetsuya Mitsudomi
Archives of Toxicology|May 19, 2015
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivityKenichi Suda, Tetsuya Mitsudomi
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Development of personalized treatments in lung cancer: focusing on the <i>EGFR</i> mutations and beyondKenichi Suda, Tetsuya Mitsudomi
Pageof 13